Recruiting
Phase 1
Phase 2

Acne mRNA Vaccine

Sponsor:

Sanofi

Code:

NCT07756957

Conditions

Acne

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Acne mRNA (messenger ribonucleic acid) vaccine

Placebo

Study Details

Brief summary:

The purpose of this study is to assess the safety profile of intramuscular injections of the Acne mRNA vaccine at 3 dose levels compared with placebo in 12 to 17 years old participants with moderate to severe acne.

An early safety data review (ESDR) will be conducted after each subcohort has completed an injection round; enrollment of the next higher dose level subcohort or progression of a subcohort to the subsequent injection round will only proceed if no safety concerns are identified. This sequential process will allow a cautious approach to vaccine injection in the adolescent population.

Study details are as follows:

  • Before being enrolled in the study, participants complete a 4-week (ie, 1-month) screening period during which they will be called over the telephone approximately in the middle of the screening period to check they are not using prohibited medications and to remind them about the facial hygiene requirements.
  • Once the screening period has been completed, the study duration will be up to 13 months for each participant
  • Participants will be invited to a long-term extension study through a separate protocol.

Conditions

Acne

Study ID

NCT07756957

Start date

Oct 14, 2026

Status verified date

Nov, 2026

Completion date

Feb 19, 2029

Anticipated

Primary completion date

Jul 19, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Aged 12 to 17 years on the day of the first study intervention administration
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator
  • Clinical diagnosis of moderate or severe facial acne vulgaris with Investigator's Global Assessment (IGA) score of Moderate or Severe (grade 3 or grade 4 on the 5-grade IGA scale) and ≥ 25 non-inflammatory lesions (ie, open and closed comedones) and ≥ 20 inflammatory lesions (ie, papules and pustules) and ≤ 2 nodulocystic lesions (ie, nodules and cysts)

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study intervention(s) or products with the same substances
  • Active nodulocystic acne, acne conglobate, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica)
  • Use of any acne-affecting treatment without an appropriate wash-out period
  • Any vaccine given in the 4 weeks before or after any injection of study intervention
  • Previous vaccination against C. acnes with an investigational vaccine
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Design

Enrollment

410 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Dose 1 sub-cohort - Group 1

3 injections

placebo comparator: Dose 1 sub-cohort - Group 2

3 injections

experimental: Dose 2 sub-cohort - Group 3

3 injections

placebo comparator: Dose 2 sub-cohort - Group 4

3 injections

experimental: Dose 3 sub-cohort - Group 5

3 injections

placebo comparator: Dose 3 sub-cohort - Group 6

3 injections

experimental: Dose 1 main cohort - Group 7

3 injections

experimental: Dose 2 main cohort - Group 8

3 injections

experimental: Dose 3 main cohort - Group 9

3 injections

placebo comparator: Main cohort - Group 10

3 injections

Interventions

Acne mRNA (messenger ribonucleic acid) vaccine

IM injection

Placebo

IM injection

Primary outcome measure

  • Unsolicited systemic AEs (Adverse Events) [ Time Frame: 30 minutes after each injection ]
  • Solicited injection site and systemic adverse reactions [ Time Frame: 8 days, including the day of each injection ]
  • Unsolicited AEs [ Time Frame: 28 days, including the day of each injection ]
  • SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuation [ Time Frame: Up to 2 months after last injection ]
  • Out-of-range biological test results (including shift from baseline values) [ Time Frame: Within 8 days after each injection, including the day of injection ]

Central Contacts and Locations

Central contacts

Trial Transparency email recommended (Toll free for US & Canada)

800-633-1610Contact-US@sanofi.com

Locations

Investigational Site Number : 1240001

Recruiting

Edmonton, Alberta, Canada, T5J 3S9

Investigational Site Number : 1240013

Recruiting

Edmonton, Alberta, Canada, T6w 0J5

Investigational Site Number : 1240009

Recruiting

Vancouver, British Columbia, Canada, V6C 0C3

More Information

Sponsor

Sanofi

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Sanofi on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.